Gyre Therapeutics Inc. (GYRE) | Stock Price, Analysis, News, Fundaments & Technical Information

stock

Gyre Therapeutics Inc.

NASDAQ | GYRE

8.86

USD

0.00 ( 0.00%)

AT CLOSE (AS OF May 5, 2025)

$868M

MARKET CAP

185.2

P/E Ratio

0.05

EPS

$19

52 Week High

$6.1

52 Week Low

LIFE SCIENCES

Sector

GYRE Chart

Area

GYRE Technicals

Tags:

GYRE Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	$102M
Total Revenue	$106M
Cost Of Revenue	$3.9M
Costof Goods And Services Sold	$3.9M
Operating Income	$16M
Selling General And Administrative	$16M
Research And Development	$12M
Operating Expenses	$86M
Investment Income Net	-
Net Interest Income	$1.5M
Interest Income	$1.5M
Interest Expense	-
Non Interest Income	-
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	$1.6M
Income Before Tax	$23M
Income Tax Expense	$5.3M
Interest And Debt Expense	-
Net Income From Continuing Operations	$18M
Comprehensive Income Net Of Tax	-
Ebit	$16M
Ebitda	$18M
Net Income	$12M

Revenue & Profitability

Earnings Performance

GYRE Financials

Highlights

Balance Sheet

Cash Flow

Income Statement

Yearly

Quarterly

yearly Balance Sheet (As of Dec 31, 2024)

Field	Value (USD)
Total Assets	$125M
Total Current Assets	$65M
Cash And Cash Equivalents At Carrying Value	$12M
Cash And Short Term Investments	$12M
Inventory	$6.3M
Current Net Receivables	$29M
Total Non Current Assets	$61M
Property Plant Equipment	-
Accumulated Depreciation Amortization Ppe	-
Intangible Assets	$273K
Intangible Assets Excluding Goodwill	$273K
Goodwill	-
Investments	-
Long Term Investments	$25M
Short Term Investments	$15M
Other Current Assets	$2.6M
Other Non Current Assets	-
Total Liabilities	$27M
Total Current Liabilities	$20M
Current Accounts Payable	$108K
Deferred Revenue	-
Current Debt	-
Short Term Debt	$713K
Total Non Current Liabilities	$7.5M
Capital Lease Obligations	$1.6M
Long Term Debt	-
Current Long Term Debt	-
Long Term Debt Noncurrent	-
Short Long Term Debt Total	$1.6M
Other Current Liabilities	$16M
Other Non Current Liabilities	$7K
Total Shareholder Equity	$63M
Treasury Stock	-
Retained Earnings	-$73M
Common Stock	$86K
Common Stock Shares Outstanding	$102M

yearly Cash Flow (As of Dec 31, 2024)

Field	Value (USD)
Operating Cashflow	-$3.6M
Payments For Operating Activities	-
Proceeds From Operating Activities	-
Change In Operating Liabilities	-
Change In Operating Assets	-
Depreciation Depletion And Amortization	$1.6M
Capital Expenditures	$2.3M
Change In Receivables	-
Change In Inventory	-$2.1M
Profit Loss	-
Cashflow From Investment	-
Cashflow From Financing	$2.1M
Proceeds From Repayments Of Short Term Debt	-
Payments For Repurchase Of Common Stock	-
Payments For Repurchase Of Equity	-
Payments For Repurchase Of Preferred Stock	-
Dividend Payout	-
Dividend Payout Common Stock	-
Dividend Payout Preferred Stock	-
Proceeds From Issuance Of Common Stock	-
Proceeds From Issuance Of Long Term Debt And Capital Securities Net	-
Proceeds From Issuance Of Preferred Stock	-
Proceeds From Repurchase Of Equity	-
Proceeds From Sale Of Treasury Stock	-
Change In Cash And Cash Equivalents	-
Change In Exchange Rate	-
Net Income	$18M

yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	$102M
Total Revenue	$106M
Cost Of Revenue	$3.9M
Costof Goods And Services Sold	$3.9M
Operating Income	$16M
Selling General And Administrative	$16M
Research And Development	$12M
Operating Expenses	$86M
Investment Income Net	-
Net Interest Income	$1.5M
Interest Income	$1.5M
Interest Expense	-
Non Interest Income	-
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	$1.6M
Income Before Tax	$23M
Income Tax Expense	$5.3M
Interest And Debt Expense	-
Net Income From Continuing Operations	$18M
Comprehensive Income Net Of Tax	-
Ebit	$16M
Ebitda	$18M
Net Income	$12M

Dividends

Field	Value
Ex Dividend Date	2023-01-13
Declaration Date	2022-12-27
Record Date	2023-01-05
Payment Date	2023-01-12
Amount	0.24

GYRE News

GYRE Profile

Gyre Therapeutics Inc. Profile

Sector: LIFE SCIENCES

Industry: PHARMACEUTICAL PREPARATIONS

None